Ose Immunotherapeutics 주식 가격. 0RAD - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

가격

4.12

매수가

0.00

매도가

0.00

거래량

0.00 일간 변동폭 0.00

4.12 52주 범위 4.12

market_cap

89.202M

전일 종가

4.12

개장가

최근 거래 시간

6.68

(O)

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

201

발행 주식

21,651,000

배당수익률

주가수익률

-6.20

주당순이익(EPS)

-1.06

매출

2.23M

순이익

-23M

섹터

Coml Physical, Biologcl Resh

산업

Coml Physical, Biologcl Resh

웹사이트

www.ose-immuno.com

본부

Nantes, Loire-atlantique, Fra

설립됨

Ose Immunotherapeutics Sa is listed in the Coml Physical, Biologcl Resh sector of the 런던증권거래소 with ticker 0RAD. The last closing price for Ose Immunotherapeutics was 4.12 €. Over the last year, Ose Immunotherapeutics shares have traded in a share price range of 4.12 € to 4.12 €.

Ose Immunotherapeutics currently has 21,651,000 shares in issue. The market capitalisation of Ose Immunotherapeutics is 89.20 € million. Ose Immunotherapeutics has a price to earnings ratio (PE ratio) of -6.20.

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO...

OSE Immunotherapeutics présente les résultats complets d’induction de l’étude Phase 2 de l’anticorps monoclonal anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO

OSE Immunotherapeutics présente les résultats complets d’induction de l’étude Phase 2 de l’anticorps monoclonal anti-IL-7R Lusvertikimab dans la...

OSE Immunotherapeutics présente des données précliniques positives sur l'anti-IL-7 récepteur Lusvertikimab en combinaison dans la colite chronique En présentation orale au 20ème congrès de l’ECCO

OSE Immunotherapeutics présente des données précliniques positives sur l'anti-IL-7 récepteur Lusvertikimab en combinaison dans la colite...

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral...

Informations relatives au nombre total de droits de vote et d’actions composant le capital

Informations relatives au nombre total de droits de vote et d’actions composant le capital Informations relatives au nombre total de droits de...

OSE Immunotherapeutics et Scienta Lab annoncent un accord stratégique portant sur ’Intelligence Artificielle appliquée à l’immunothérapie de précision

OSE Immunotherapeutics et Scienta Lab annoncent un accord stratégique portant sur ’Intelligence Artificielle appliquée à l’immunothérapie de...

OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy

OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy OSE...

OSE Immunotherapeutics présentera trois abstracts sur Lusvertikimab, son anticorps anti-IL-7 récepteur dans la rectocolite hémorragique, au 20ème congrès annuel de l’ECCO

OSE Immunotherapeutics présentera trois abstracts sur Lusvertikimab, son anticorps anti-IL-7 récepteur dans la rectocolite hémorragique, au 20ème...

OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO OSE...

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief...

기간	시가	고가	저가	평균 일일 거래량	VWAP
1	4.12	4.12	4.12	202	4.12	DE
4	4.12	4.12	4.12	187	4.12	DE
12	4.12	4.12	4.12	201	4.12	DE
26	4.12	4.12	4.12	145	4.12	DE
52	4.12	4.12	4.12	231	4.12	DE
156	4.12	4.12	4.12	760	4.12	DE
260	4.12	4.12	4.12	893	4.12	DE

0RAD - Frequently Asked Questions (FAQ)

What is the current Ose Immunotherapeutics share price?

The current share price of Ose Immunotherapeutics is 4.12 €

How many Ose Immunotherapeutics shares are in issue?

Ose Immunotherapeutics has 21,651,000 shares in issue

What is the market cap of Ose Immunotherapeutics?

The market capitalisation of Ose Immunotherapeutics is EUR 89.2M

What is the 1 year trading range for Ose Immunotherapeutics share price?

Ose Immunotherapeutics has traded in the range of 4.12 € to 4.12 € during the past year

What is the PE ratio of Ose Immunotherapeutics?

The price to earnings ratio of Ose Immunotherapeutics is -6.2

What is the cash to sales ratio of Ose Immunotherapeutics?

The cash to sales ratio of Ose Immunotherapeutics is 64.04

What is the reporting currency for Ose Immunotherapeutics?

Ose Immunotherapeutics reports financial results in EUR

What is the latest annual turnover for Ose Immunotherapeutics?

The latest annual turnover of Ose Immunotherapeutics is EUR 2.23M

What is the latest annual profit for Ose Immunotherapeutics?

The latest annual profit of Ose Immunotherapeutics is EUR -23M

What is the registered address of Ose Immunotherapeutics?

The registered address for Ose Immunotherapeutics is 22 BOULEVARD DE BENONI GOULLIN, NANTES, LOIRE-ATLANTIQUE, 44200

What is the Ose Immunotherapeutics website address?

The website address for Ose Immunotherapeutics is www.ose-immuno.com

Which industry sector does Ose Immunotherapeutics operate in?

Ose Immunotherapeutics operates in the COML PHYSICAL, BIOLOGCL RESH sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
ADMEAdm Energy Plc	0.22p (46.67%)	20.89M
PATPanthera Resources Plc	12.00p (26.32%)	5.85M
MET1Metals One Plc	0.55p (22.22%)	4.28M
GSCUGreat Southern Copper Plc	3.05p (22.00%)	23.3M
PXCPhoenix Copper Limited	3.30p (20.00%)	4M
SFRSeverfield Plc	25.90p (-45.70%)	14.25M
WBIWoodbois Limited	0.0375p (-20.21%)	73.39M
GWMOGreat Western Mining Corporation Plc	0.0085p (-19.05%)	307.13M
PRMProteome Sciences Plc	3.72p (-17.52%)	969.96k
NTOGNostra Terra Oil And Gas Company Plc	0.026p (-17.46%)	309.6M
SYMESupply@me Capital Plc	0.0036p (12.50%)	772.28M
MSMNMosman Oil And Gas Limited	0.0305p (-7.58%)	385.06M
NTOGNostra Terra Oil And Gas Company Plc	0.026p (-17.46%)	309.6M
GWMOGreat Western Mining Corporation Plc	0.0085p (-19.05%)	307.13M
TRPTower Resources Plc	0.0235p (-4.08%)	265.75M

ITYS 54 초 전

MORE $ volume today than GEVI made last Q ;-)
GEVI gotta ramp SH^% up before K comes out !!!!

GEVI

ITYS 54 초 전

MORE $ volume today than GEVI made last Q ;-)
GEVI gotta ramp SH^% up before K comes out !!!!

GEVI

KingGalaxy91 58 초 전

This is getting annoying.

I am NOT KingGalaxy91

I post as zipjet.

Not sure what it happening.

johnydollar 1 분 전

If only that was true.........

If there was nothing left to see 👀.........

Then the genius.......

Would have moved on to what they call.....

The top of the cream .......

la crème de la crème........

&#x

DBMM

PennyMillions852 1 분 전

Still thin up to .0085, but ask slaps are needed!

IGPK

Monksdream 1 분 전

BIAF, new 52 week low

https://investorshub.advfn.com/uimage/uploads/2025/3/3/hnljhIMG_5550.gif

BIAF

Urocka 2 분 전

Deep Deep Red.... they did actually post a few posts on Instagram over the weekend featured at a Vendor Day in the Seattle area.

PVSP

delerious1 2 분 전

The only thing Green today is big Pharma and Healthcare

NBRI

pdmihopefull 2 분 전

Nope....no biggie...no money to be made in humble..,

CAFI

RobotDroid 2 분 전

Welcome to my esteemed ignore list.

NWBO

janice shell 2 분 전

There are reports he had something on President Biden...

That's absurd. But I'll betcha Putin does have something on Trump.

Stinger2014 2 분 전

Oh yea! Glad $CGAC missed the market disaster today.

CGAC

linkvest 3 분 전

Almost all of my stocks are red today.....

IGPK

DewDiligence 3 분 전

[OT]—Send a private message to [iHub admin] by clicking on this link:

https://investorshub.advfn.com/secure/post_prvt.aspx?user=111041

lflhdy 3 분 전

That is what I am waiting for, With almost 211 million shares outstanding and a R/S pending this is not the time to buy. The price is nice but in percentage to the price after the R/S it is still to high.

IQST

ITYS 3 분 전

FINRA surely will wrap this N&S this week. IF they completed everything as Company stated then usually 3-8 business days to implement changes. C'mon FINRA, our patience is running thin !!

MGON

Miamifl 3 분 전

Over 400,000 shares for most of the day, and now over 46,000,000 shares ALL OF A SUDDEN.

Any explanation???

BIEL

ducci1 3 분 전

Scalped 1/2 582C .96! DD Take It !

SPY

Fdc4 3 분 전

There are always unanswered questions in VIADERMA!!! Dejavú?!!

VDRM

rbb 3 분 전

other than falling through support.... smh

FDCT

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Ose Immunotherapeutics Sa (0RAD) 시세

Ose Immunotherapeutics Sa (0RAD)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

Ose Immunotherapeutics Sa 정보

0RAD 최신 뉴스

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics présente les résultats complets d’induction de l’étude Phase 2 de l’anticorps monoclonal anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO

OSE Immunotherapeutics présente des données précliniques positives sur l'anti-IL-7 récepteur Lusvertikimab en combinaison dans la colite chronique En présentation orale au 20ème congrès de l’ECCO

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO

Informations relatives au nombre total de droits de vote et d’actions composant le capital

OSE Immunotherapeutics et Scienta Lab annoncent un accord stratégique portant sur ’Intelligence Artificielle appliquée à l’immunothérapie de précision

OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy

OSE Immunotherapeutics présentera trois abstracts sur Lusvertikimab, son anticorps anti-IL-7 récepteur dans la rectocolite hémorragique, au 20ème congrès annuel de l’ECCO

OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

OSE Immunotherapeutics présente les résultats complets d’induction de l’étude Phase 2 de l’anticorps monoclonal anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics présente des données précliniques positives sur l'anti-IL-7 récepteur Lusvertikimab en combinaison dans la colite chronique En présentation orale au 20ème congrès de l’ECCO

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO

Informations relatives au nombre total de droits de vote et d’actions composant le capital

OSE Immunotherapeutics et Scienta Lab annoncent un accord stratégique portant sur ’Intelligence Artificielle appliquée à l’immunothérapie de précision

OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy

OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics présentera trois abstracts sur Lusvertikimab, son anticorps anti-IL-7 récepteur dans la rectocolite hémorragique, au 20ème congrès annuel de l’ECCO

OSE Immunotherapeutics annonce la nomination du Dr. Sonya Montgomery au poste de Chief Development Officer

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

Ose Immunotherapeutics : Informations relatives au nombre total de droits de vote et d’actions composant le capital

0RAD - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거